Literature DB >> 15880140

Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction.

Melinda Wuest1, Juliane Hecht, Torsten Christ, Manfred Braeter, Christian Schoeberl, Oliver W Hakenberg, Manfred P Wirth, Ursula Ravens.   

Abstract

1. Besides its antimuscarinic effects, propiverine may possess an additional mode of action. We compared the effects of propiverine, three of its metabolites (M-5, M-6, M-14) and atropine in human, pig and mouse urinary bladder preparations in order to elucidate the nature of a possible additional mode of action. 2. Like the parent compound, M-5, M-6 and M-14 reduced to variable degrees the contractions elicited by electric field stimulation (EFS) of isolated, urothelium-denuded detrusor strips. In mouse the atropine-resistant and therefore the nonadrenergic, noncholinergic component of contractile response to EFS was reduced by M-5, M-14 and propiverine, but was hardly affected by M-6. 3. Atropine, propiverine and M-6 significantly shifted the cumulative concentration-response curves for carbachol (CCh) to higher concentrations. Atropine and M-6 did not affect the maximum tension induced by CCh. Propiverine, M-5 and M-14 reduced the maximum CCh effect, suggesting at least one additional mode of action. This pattern of response was observed in all the three species, albeit with some differences in sensitivity to the various agents. 4. In freshly isolated human detrusor smooth muscle cells, propiverine and M-14 inhibited the nifedipine-sensitive L-type calcium current (I(Ca)) in a concentration-dependent manner. In contrast, the effects of M-5 and M-6 on I(Ca) were insignificant in the concentration range examined. 5. The investigated responses to propiverine and its metabolites suggest that impairment of maximum CCh-induced contractions is due to strong effect on I(Ca) and that this may be associated with the presence of the aliphatic side chain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15880140      PMCID: PMC1576185          DOI: 10.1038/sj.bjp.0706244

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

Review 1.  The pharmacological treatment of urinary incontinence.

Authors:  K E Andersson; R Appell; L D Cardozo; C Chapple; H P Drutz; A E Finkbeiner; F Haab; R Vela Navarrete
Journal:  BJU Int       Date:  1999-12       Impact factor: 5.588

Review 2.  Which muscarinic receptor is important in the bladder?

Authors:  T Yamanishi; C R Chapple; R Chess-Williams
Journal:  World J Urol       Date:  2001-11       Impact factor: 4.226

Review 3.  Potential therapeutic targets for treatment of the overactive bladder.

Authors:  D J Sellers; C R Chapple; R Chess-Williams
Journal:  World J Urol       Date:  2001-11       Impact factor: 4.226

4.  Ca(2+) channel properties in smooth muscle cells of the urinary bladder from pig and human.

Authors:  Shunichi Kajioka; Shinsuke Nakayama; Gordon McMurray; Kihachiro Abe; Alison F Brading
Journal:  Eur J Pharmacol       Date:  2002-05-17       Impact factor: 4.432

5.  M(3) muscarinic receptors mediate contraction of human urinary bladder.

Authors:  Charlotte Fetscher; Marina Fleichman; Martina Schmidt; Susanne Krege; Martin C Michel
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

6.  Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle.

Authors:  A Choppin; R M Eglen
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

7.  Mechanical response to electrical field stimulation of rat, guinea-pig, monkey and human detrusor muscle: a comparative study.

Authors:  F Pessina; K Marazova; R Kalfin; G Sgaragli; A Manganelli; K Milenov
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-05       Impact factor: 3.000

8.  Cholinergic and purinergic responses in isolated human detrusor in relation to age.

Authors:  Melinda Wuest; Kathrin Morgenstern; Eva-Maria Graf; Manfred Braeter; Oliver W Hakenberg; Manfred P Wirth; Ursula Ravens
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

Review 9.  Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic).

Authors:  H Madersbacher; G Mürtz
Journal:  World J Urol       Date:  2001-11       Impact factor: 4.226

10.  The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro.

Authors:  R Chess-Williams; C R Chapple; T Yamanishi; K Yasuda; D J Sellers
Journal:  J Auton Pharmacol       Date:  2001 Oct-Dec
View more
  18 in total

1.  Functional investigation of β-adrenoceptors in human isolated detrusor focusing on the novel selective β3-adrenoceptor agonist KUC-7322.

Authors:  Yasuhiko Igawa; Tim Schneider; Yoshinobu Yamazaki; Satoshi Tatemichi; Yukio Homma; Osamu Nishizawa; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-29       Impact factor: 3.000

Review 2.  Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?

Authors:  Martin C Michel; Sharath S Hegde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11       Impact factor: 3.000

3.  Does ivabradine exhibit a role in the reduction of bladder overactivity?

Authors:  K Stamatiou; I Heretis; E Skoumbourdis
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

4.  Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue.

Authors:  Melinda Wuest; Birgit Eichhorn; Manfred Braeter; Gerhard Strugala; Martin C Michel; Ursula Ravens
Journal:  Pflugers Arch       Date:  2007-12-21       Impact factor: 3.657

Review 5.  Urothelial effects of oral agents for overactive bladder.

Authors:  Karl-Erik Andersson; Claudius Fullhase; Roberto Soler
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

6.  Age-dependent contribution of Rho kinase in carbachol-induced contraction of human detrusor smooth muscle in vitro.

Authors:  Timo Kirschstein; Chris Protzel; Katrin Porath; Tina Sellmann; Rüdiger Köhling; Oliver W Hakenberg
Journal:  Acta Pharmacol Sin       Date:  2013-10-14       Impact factor: 6.150

7.  Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine.

Authors:  Stefan Propping; Manfred Braeter; Marc-Oliver Grimm; Manfred P Wirth; Ursula Ravens; Melinda Wuest
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-02-25       Impact factor: 3.000

8.  Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder.

Authors:  Werner Siegmund; Ulla Sillén; Göran Läckgren; Frieder Schnabel; Gerd Mürtz; Cornelia Feustel
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

9.  Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination.

Authors:  Karen May; Thomas Giessmann; Danilo Wegner; Reinhard Oertel; Christiane Modess; Stefan Oswald; Manfred Braeter; Werner Siegmund
Journal:  Eur J Clin Pharmacol       Date:  2008-07-15       Impact factor: 2.953

Review 10.  Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.

Authors:  Kate McKeage
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.